ArticleJournal of translational medicine2026
PPARγ suppresses the tumorigenesis of retroperitoneal liposarcoma via inactivation of the PI3K/AKT signaling pathway.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRetroperitoneal liposarcoma (RLPS) is characterized by high heterogeneity, frequent recurrence and dismal prognosis. Surgery remains the main therapeutic strategy, while no effective targeted therapy is available for advanced RLPS. Peroxisome proliferator-activated receptor γ (PPARγ) is a core regulator of adipocyte differentiation, yet its function and regulatory mechanisms in RLPS remain unclear.
methodsEighty clinical specimens and information from RLPS patients were collected and analyzed to examine PPARγ expression and assess its prognostic value, integrated with results from multi-database. The biological functions of PPARγ were investigated by constructing viral vectors for its overexpression and knockdown in both in vivo and in vitro. Bioinformatic analysis, multiplex immunofluorescence, co-immunoprecipitation and multiple approaches were applied to elucidate PPARγ-mediated mechanisms and its crosstalk with the downstream PI3K/AKT cascade. The anti‑tumor activity and biosafety of the PPARγ agonist troglitazone (TGZ) were assessed in vitro and in RLPS Cell Line-Derived/Patient-Derived Xenograft models.
resultsPPARγ was significantly downregulated in RLPS tissues and acted as an independent prognostic predictor. Overexpression of PPARγ inhibited malignant phenotypes and promoted apoptosis of RLPS cells, whereas PPARγ knockdown exerted the opposite effects. Mechanistically, PPARγ directly bound to PI3K and exerted tumor‑suppressive functions by suppressing the phosphorylation and activation of the PI3K/AKT pathway. TGZ upregulated PPARγ expression, regulated the PI3K/AKT pathway in vitro, and exhibited robust antitumor activity alongside favorable biosafety in vivo.
conclusionsPPARγ exerts antitumor effects via inactivation of the PI3K/AKT signaling pathway and serves as an independent prognostic biomarker in RLPS. The PPARγ agonist TGZ holds great potential as an antitumor drug candidate for RLPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.